Breast surgery for patients with de novo metastatic breast cancer: A meta-analysis of randomized controlled trials.

The role of breast surgery in the treatment of patients with de novo metastatic breast cancer(dnMBC) remains controversial, with conflicting trial results. We did a meta-analysis to comprehensively investigate and assess whether breast surgery is associated with survival and quality of life outcomes in patients with dnMBC.We systematically searched PubMed, Embase, Google Scholar, Scopus, and Web of Science, from database inception to March 30, 2022, for randomized controlled trials(RCTs) that compared breast surgery or locoregional therapy with non-surgical treatment based on systemic therapy for managing dnMBC.

Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study.

Whether locoregional therapy (LRT) should be performed in patients with de novo metastatic breast cancer (dnMBC) has been debated. Here we report the survival outcomes of LRT in patients with dnMBC, focusing on the association of surgical timings and surgical margins with survival in this patient population. The retrospective study included patients with dnMBC in our hospital, between March 1, 2007 and December 31, 2017.

Preparation of ferulic acid-grafted chitosan using recombinant bacterial laccase and its application in mango preservation.

To improve the antioxidant and antibacterial properties of chitosan, recombinant bacterial laccase from fmb-103 (fmb-rL103) was used to catalyze ferulic acid grafting. The grafted chitosan was characterized using UV-vis and FT-IR techniques. DPPH free radical scavenging results indicated that the antioxidant properties of the grafted chitosan (FA--CS) were significantly improved.